Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias Leukemia (2010) The majority of adult acute myeloid leukemias (AMLs) have normal cytogenetics and lack a balanced translocation with a known fusion gene. They occur de novo or after a chronic phase (hereafter called primary and secondary, respectively). They are poorly understood and heterogeneous in terms of bioclinical presentation and prognosis, as well as in terms of molecular targets. The identification of mutations in several genes, such as NPM1 and FLT3, has revealed prognosis subgroups and modified their clinical management. 1 A better molecular characterization should further improve both the understanding of the physiopathology and the treatment of these leukemias.
The additional sex comb-like 1 (ASXL1) gene, located in the chromosomal region 20q11, belongs to a family of three identified members that encode poorly characterized proteins regulating chromatin remodeling. The ASXL proteins contain a C-terminal PHD (Plant Homeo Domain) finger and belong to the polycomb and trithorax complexes, which regulate the genetic program of stem cells. We have recently shown that ASXL1 is mutated in roughly 10% of myelodysplastic syndromes, 2 10% of myeloproliferative neoplasms 3 and 40% of chronic myelomonocytic leukemias. 2 Using array comparative genomic hybridization (aCGH), we also observed a deletion of the ASXL1 locus in a myelodysplastic syndrome case. 2 These observations suggest that ASXL1 is a tumor suppressor whose haploinsufficiency has a role in myeloid diseases. The predicted truncated ASXL1 protein would lack its PHD finger, which could prevent it from binding methylated histone lysines and interacting with chromatin modifiers, thus enhancing self-renewal in hematopoietic progenitors. 4 To determine whether ASXL1 is involved in AML, we used DNA sequencing and aCGH to search for mutations and deletions of the gene in 46 cases of AML with normal karyotype and 17 cases with trisomy 8 (n ¼ 14), 9q deletion (HD-0632), trisomy 11 (HD-0304) or 20q11-13 deletion (HD-0381) as a sole karyotypic abnormality. The 63 AMLs were 46 primary cases and 17 transformations of a previous myeloid disease (of which seven have been previously reported 2 ). We did not include therapy-related AMLs. All patients signed an informed consent and the study was approved by our institutional review board. We have previously described primers and conditions for ASXL1 DNA amplification and sequencing. 2 Fifty cases were also studied by aCGH with high-density oligonucleotide arrays (Hu-244A, Agilent Technologies, Massy, France), as previously described. 5 We also searched for mutations in CEBPA (exons 1-8), FLT3 (internal tandem duplicationsFITDsFand point mutation in exon 20-encoded kinase domainFTKD), JAK2 (exon 14), K and NRAS (exons 1 and 2), and NPM1 (exon 12), as well as in CXXC5, FES and TAL1, three genes found altered by gain or loss in aCGH analysis.
In all, 41 out of the 50 cases studied by aCGH did not show any copy number aberration (isolated trisomy 8 was not taken into account). The deletion of chromosomal region 20q11-13 (HD-0381), which was visible on the karyotype, involved ASXL1 (Table 1) . We found heterozygous nonsense or frameshift mutations of ASXL1 in 11 out of the 63 cases (B17.5%) ( Table 1) . We also found several cases of substitution, which we did not take into account because they may represent polymorphisms. Thus, in total, 12 cases out of 63 showed ASXL1 alteration (19%). In two cases, we sequenced ASXL1 in DNA extracted from buccal smears of the patient with ASXL1 mutation; ASXL1 was not mutated, showing that the mutation was acquired.
In agreement with what is known for AML with normal karyotype, 5 almost half of the cases (28 out of 63, 44%) showed exon 12 NPM1 mutations. NPM1 mutations were mutually exclusive with ASXL1 alterations: none of the 28 NPM1-mutated cases showed ASXL1 mutation or deletion, whereas 12 out of the 35 (34%) non-NPM1-mutated cases were mutated or deleted for ASXL1 (P ¼ 0.0018). Three ASXL1 missense mutations, for which we do not know whether they are acquired or not, were also detected in cases without NPM1 mutations. FLT3 mutations (n ¼ 6) and ITD (n ¼ 14) were found in 19 cases (30%) and were not observed with ASXL1 mutations except in one case (HD-0282). Three cases were mutated in either K or NRAS, and one case in JAK2. Data on CEBPA, available for 11 cases, revealed no mutation. Finally, we did not find any mutation of CXXC5, FES and TAL1 genes.
Several tumor suppressors (for example, RB1, p53, RUNX1,
5
TET2, 2,3,6-13 ASXL1 2,3 ) are inactivated in various types of myeloid diseases. With respect to ASXL family members, deletions of ASXL1, ASXL2 and ASXL3 have been reported. 2, 11 Mutations of ASXL1 are found in myelodysplastic syndromes 2 and myeloproliferative neoplasms, 3 suggesting that additional alterations are responsible for acute transformation; as the AMLs studied by us were not associated with translocations, these alterations are not well-known fusion genes but other mutations. They are not mutations of NPM1 as these were mutually exclusive with ASXL1 mutations. This could suggest that the NPM1 and ASXL1 mutations are epistatic. We could speculate that ASXL1 and NPM1 have distinct functions but act at some moment on the same cellular control. One such control could be the regulation of 9p INK4A-ARF-INK4B loci, which constitute an important node for the regulation of senescence and self-renewal and are regulated by polycomb complexes as well as NPM1, a histone chaperone.
1 ASXL1 could have a role in this regulation through its interaction with polycomb proteins.
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However, by aCGH, we did not find any loss of INK4 loci in our series of AML cases. Actually, the difference between NPM1 and ASXL1 mutations may rather reflect two different routes of leukemogenesis than two alternate hits on the same route (Figure 1 ). NPM1 mutations are uncommon in AMLs secondary to a chronic myeloid disease. 1, 14 In contrast, 9 of the 17 secondary AMLs showed ASXL1 mutation or deletion (vs 3 of 46 primary AMLs, including a case with mixed lineage dysplasia, P ¼ 0.0001) and ASXL1 alterations were prominently observed in AMLs secondary to a chronic myeloid disease (9 of 12), whereas it was not the case for NPM1 mutations (2 of 28, P ¼ 0.0038) ( Table 2) . Were this hypothesis validated by the study of more cases, the detection of ASXL1 mutations would help distinguish between primary and secondary AMLs, and consequently help orient the prognosis, even in the absence of known chronic phases.
In contrast, TET2 mutations in a series of AML were found to correlate neither with the presence or absence of NPM1 or FLT3 mutations nor with an antecedent of chronic myeloid disease. 10 In another series, three of four TET2 mutations were found in secondary cases. 8 Although TET2 and ASXL1 may function in similar pathways of epigenetic regulation, 4 there might be differences in their relationship with NPM1 and in their window of action during the course of the disease. In the case that has both ASXL1 and FLT3 alteration, we determined that the ASXL1 mutation, but not the FLT3 ITD, was present at the chronic phase, suggesting that the ASXL1 and FLT3 mutations can cooperate in rare cases. Finally, the rare RAS mutations occurred indifferently in primary or secondary cases; one was found in an ASXL1-mutated case, which was not unexpected, as we have previously shown that RAS and ASXL1 mutations can co-occur. 2 It will now be interesting to determine what other alterations can associate with either the NPM1 or ASXL1 route of leukemogenesis.
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The authors declare no conflict of interest. , V Gelsi-Boyer Figure 1 A model for a distinct role of ASXL1 and NPM1 mutations in the development of acute myeloid leukemia (AML) with normal karyotype. A hematopoietic stem or progenitor cell acquires a first mutation. Second hits, which target NPM1 and/or FLT3 and/or other mutation(s), induce strong reprogramming and lead to AML. Alternatively, second hits in ASXL1 and/or other genes induce an overt or asymptomatic chronic phase that may progress to secondary AML (sAML) with the occurrence of additional mutation(s). No ATRA administered during protocol maintenance therapy.
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